Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (48)

2024

  1. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 9, Núm. 1

  2. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 8, Núm. 1

2021

  1. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 6, Núm. 1

  2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)

    EJNMMI Radiopharmacy and Chemistry, Vol. 6, Núm. 1

  3. In vivo SPECT-CT imaging and characterization of technetium-99m-labeled bevacizumab-loaded human serum albumin pegylated nanoparticles

    Journal of Drug Delivery Science and Technology, Vol. 64

2020

  1. Incidental diagnosis of neuroendocrine tumour with 68Ga-PSMA PET/CT: Report of clinical case

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 39, Núm. 2, pp. 102-103

  2. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

    European Journal of Nuclear Medicine and Molecular Imaging

2018

  1. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Journal of Controlled Release, Vol. 276, pp. 125-139

2017

  1. European regulations for the introduction of novel radiopharmaceuticals in the clinical setting

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 61, Núm. 2, pp. 135-144

  2. Position statement on radiopharmaceutical production for clinical trials

    EJNMMI Radiopharmacy and Chemistry, Vol. 2, Núm. 1

2016

  1. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency

    Human Molecular Genetics, Vol. 25, Núm. 7, pp. 1318-1327

2015

  1. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 97, pp. 280-289

  2. Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: A concise overview and practical guidance for a risk-based approach

    Nuclear Medicine Communications, Vol. 36, Núm. 5, pp. 414-422

  3. Zein nanoparticles for oral folic acid delivery

    Journal of Drug Delivery Science and Technology, Vol. 30, pp. 450-457

2012

  1. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles

    Journal of Controlled Release, Vol. 162, Núm. 3, pp. 553-560

  2. PET tracers for clinical imaging of breast cancer

    Journal of Oncology

  3. Toxicity studies of poly(anhydride) nanoparticles as carriers for oral drug delivery

    Pharmaceutical Research, Vol. 29, Núm. 9, pp. 2615-2627

2011

  1. Adeno-associated virus liver transduction efficiency measured by in vivo [ 18F]FHBG positron emission tomography imaging in rodents and nonhuman primates

    Human Gene Therapy, Vol. 22, Núm. 8, pp. 999-1009

  2. MAPC transplantation confers a more durable benefit than AC133+ cell transplantation in severe hind limb ischemia

    Cell Transplantation, Vol. 20, Núm. 2, pp. 259-269